Advanced Solid Tumor
Who we are
MAQ-001 in Patients With Advanced Solid Tumors
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
A Phase 1/2 of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
